Drugs / Recombinant human urokinase
Recombinant human urokinase
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03578822 | Aug 2018 → Feb 2020 | ischemic stroke | Tasly Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03541668 | May 2018 → Apr 2020 | ischemic stroke | Tasly Biopharmaceuticals Co., Ltd. | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human urokinase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03541668 ↗ |
| Known as | Recombinant human prourokinase | “Recombinant human prourokinase (rhPro-UK) is a thrombolytic agent” PMID 37490291 ↗ Jul 2023 |
| Known as | Recombinant prourokinase | “Recombinant prourokinase (rhPro-UK) is a specific plasmin activator” PMID 38907679 ↗ Aug 2024 |
| Modality | Protein / enzyme biologic | “Recombinant human urokinase” NCT03578822 ↗ |
| Route | Intravenous | “Eligible patients were randomly assigned (1:1) to receive intravenous rhPro-UK or alteplase” PMID 37490291 ↗ Jul 2023 |